Bremelanotide, a melanocortin receptor agonist, has been FDA-approved as an as-needed treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials demonstrated statistically significant improvements in sexual desire and reductions in distress related to low libido, though the overall clinical benefit was considered modest. Administered via subcutaneous injection
